ProQR Therapeutics N.V. Stock
Price
Target price
€1.61
€1.61
-1.290%
-0.021
-1.290%
€3.48
19.06.26 / Stuttgart Stock Exchange
WKN: A12B97 / Symbol: PRQR / Name: ProQR / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
ProQR Therapeutics N.V. Stock
A loss of -1.290% shows a downward development for ProQR Therapeutics N.V..
Our community is currently high on ProQR Therapeutics N.V. with 5 Buy predictions and 0 Sell predictions.
With a target price of 3 € there is a hugely positive potential of 86.45% for ProQR Therapeutics N.V. compared to the current price of 1.61 €.
Our community identified positive and negative aspects for ProQR Therapeutics N.V. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the ProQR Therapeutics N.V. stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | -1.290% | 30.178% | 31.562% | -1.650% | -4.283% | 4.277% | -72.017% |
| Pharming Group | 1.610% | 1.121% | 4.253% | 26.260% | -21.099% | 5.472% | 17.301% |
| Formycon AG | 1.520% | -4.175% | 8.462% | -25.085% | -22.740% | -70.493% | -67.586% |
| Heron Therapeutics Inc. | -1.100% | 4.430% | -50.410% | -79.126% | -67.415% | -67.297% | -97.234% |
Comments
ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (PRQR) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $9.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat